CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


patients COVID 19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D000066553 Problem Behavior NIH 0.38
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000708 Behavioral abnormality HPO 0.38

There is one clinical trial.

Clinical Trials


1 Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19

The RT-PCR on rhino-pharynge sampling highlights the genetic material of the virus and indicates that a subject is infected with SARS-CoV-2. This test can be in about 30% of false negative cases, it does not allow to date the infection, nor to predict the asymptomatic, mild, moderate or severe evolution of the disease. In terms of public health, we need 1/ to better understand the chronology of the immune response to the virus in the general population and in contacts of index cases; 2/ To know which characteristics of the immune response are protective of future reinfections. Finally, in symptomatic subjects, we need biomarkers that predict the evolutionary mode of the disease (moderate vs. severe form).

NCT04418206 Covid 19 Other: patients COVID 19

Primary Outcomes

Description: Proportion of subjects with IgA-specific cells of SARS-CoV-2's Spike 1 protein at inclusion and 7 +/-2 days later

Measure: IgA specific cells of SARS

Time: At 7 days

Secondary Outcomes

Description: The scale is 7-point ordinal.

Measure: OMS progression scale

Time: At 7 days


No related HPO nodes (Using clinical trials)